Introduction
============

Amino acids (AAs) enter cells *via* transport mediated by specific plasmatic membrane proteins [@B1], [@B2], also known as AA transporters that are highly up-regulated in various malignant tumors in comparison to normal tissues (*e.g.*, systems L, ASC, and A) [@B3]-[@B9]. Targeting the elevated expression of AA transporters is an effective way to design the radiolabelled AAs as tumor-specific imaging tracers. No surprise, positron-labelled AAs have been an important class of radiopharmaceuticals for positron emission tomography (PET) imaging of cancer (*e.g.*, prostate, breast, and brain cancer) [@B10]-[@B17].

Initial applications and studies mainly focused on the naturally occurring AAs, because carbon-11 (^11^C) can be easily incorporated into AAs without any effects on biological properties [@B18]-[@B21]. Sulfur-containing AAs (SAAs) play many physiological and metabolic roles in living systems, such as protein synthesis, methylation of DNA, and biosynthesis of glutathione [@B22]. L-methyl-\[^11^C\]methionine (\[^11^C\]MET, **Figure [S1](#SM0){ref-type="supplementary-material"}A**), an essential SAA labelled with ^11^C, has been extensively used for brain tumor imaging [@B23]-[@B27]. Compared with clinically used 2-\[^18^F\]fluoro-2-deoxy-D-glucose (\[^18^F\]FDG), \[^11^C\]MET accumulates preferentially in tumor cells but poorly in normal brain cells, thus providing a higher sensitivity to detect brain tumors [@B26], [@B28], [@B29]. However, \[^11^C\]MET is taken up not only by tumors but also by other inflammatory lesions, leading to low tumor specificity [@B30]-[@B33]; additionally, it is susceptible to *in vivo* metabolism [@B34], complicating kinetic analysis. To address these deficiencies, *S-*\[^11^C\]-methyl-L-cysteine **1L** (*S*-\[^11^C\]CH~3~-L-CYS) and *S-*\[^11^C\]-methyl-D-cysteine **1D** (*S*-\[^11^C\]CH~3~-D-CYS), a pair of ^11^C-labelled *S*-methylcysteine enantiomers (**Figure [1](#F1){ref-type="fig"}A** and **Figure [S1](#SM0){ref-type="supplementary-material"}B**), were successively developed *via* ^11^C-isotopic substitution in our previous studies [@B35]-[@B38]. Preliminary studies indicated that the tracers were superior to \[^18^F\]FDG and \[^11^C\]MET in the differentiation of tumor from inflammation [@B35], [@B36], [@B38]-[@B40]. Nevertheless, the short half-life of ^11^C (*t*~1/2~ = 20.4 min) restricts the widespread application of these tracers, resulting in an urgent demand for ^18^F-labelled SAA tracers (^18^F,*t*~1/2~ = 109.8 min).

To date, most previous studies on the ^18^F-labelled SAA tracers (**Figure [S1](#SM0){ref-type="supplementary-material"}B**) have concentrated on molecular scaffolds which can be readily radiolabelled by linking with a prosthetic group, such as *S*-(2-\[^18^F\]fluoroethyl)-L-homocysteine [@B41], [@B42], *S*-(3-\[^18^F\]fluoropropyl)-L-homocysteine [@B43], *S*-(3-\[^18^F\]fluoropropyl)-D-homocysteine [@B43], [@B44]. For the structure-sensitive SAA molecules, however, even minor side-chain alterations caused by the prosthetic groups (*S*-ethyl and *S*-propyl) may lead to significant changes in biological properties. More recently, to avoid affecting the biological activity, ^18^F-B-MET (a methionine boramino acid derivative; **Figure [S1](#SM0){ref-type="supplementary-material"}B**) was developed as a potential substitute of \[^11^C\]MET by isosteric substitution of carboxylate (-CO~2~^-^) group with trifluoroborate (-BF~3~^-^) group [@B45]. ^18^F-B-MET shared the same AA transport systems with \[^11^C\]MET owing to the nearly identical charge distribution patterns. But these groups (-BF~3~^-^ and -CO~2~^-^) differ considerably in chemical structure and properties, which may cause potential differences in metabolism of the tracers *in vivo*. Therefore, despite these undeniable successes, the development of ^18^F-labelled SAA tracers without significant structural changes or relying on prosthetic groups remains to be a great challenge, highlighting the importance of research on a structure-mimetic tracer.

Trifluoromethyl (-CF~3~), the smallest symmetrical multi-fluorine group, has captured intense attention in the fields of chemistry and pharmacy, because of its ability to increase chemical and metabolic stability, to improve bioavailability and lipophilicity, and to enhance binding selectivity [@B46]-[@B50]. Given these advantages of -CF~3~ and our interest in ^18^F-labelled SAA tracers, in this work, we aimed to develop a couple of ^18^F-trifluoromethylated cysteine enantiomers for PET imaging of glioma. As shown in **Figure [1](#F1){ref-type="fig"}B**, *S*-\[^18^F\]CF~3~-L-CYS **2L** and *S*-\[^18^F\]CF~3~-D-CYS **2D** were designed by replacement of methyl (-CH~3~) group with -\[^18^F\]CF~3~ group according to a structure-based bioisosterism strategy. Encouragingly, this proposal received great support from the calculated molecular electrostatic potential (MEP) maps of the *S*-methylcysteines and their mimics (**Figure [1](#F1){ref-type="fig"}C**). Herein, we report the synthesis of enantiopure **2L** and **2D** starting from serine-derived cyclic-sulfamidates *via* a nucleophilic ^18^F-trifluoromethylthiolation reaction, and also describe preliminary *in vitro* and *in vivo* biological evaluation.

Results and Discussion
======================

Radiochemistry
--------------

Although the development of the ^18^F-trifluoromethylated SAA tracers is conceptually straightforward, it is actually quite challenging due to the difficulty of introducing fluorine-18 into the radiolabelled -SCF~3~ group. The most efficient synthetic routes toward non-labelled trifluoromethylated SAAs involve direct trifluoromethylation of thiols using electrophilic trifluoromethylating reagents, such as the Togni\'s [@B51], [@B52] and Umemoto\'s [@B53] reagents. However, until recently, only one such radiolabelled reagent (^18^F-Umemoto\'s reagent) was successfully developed for electrophilic ^18^F-trifluoromethylation [@B54]. In addition, Liang and Xiao reported a nucleophilic ^18^F-trifluoromethylthiolation of α-bromo carbonyl compounds and aliphatic halides with difluorocarbene (generated from Ph~3~P^+^CF~2~CO~2~^-^; PDFA) in the presence of ^18^F-fluoride and elemental sulfur (S~8~) [@B55], [@B56]. Cahard and Ma recently developed a straightforward method for the synthesis of β- and γ-SCF~3~ α-AA derivatives through nucleophilic trifluoromethylthiolation of cyclic sulfamidates [@B57]. Moreover, serine-derived cyclic sulfamidates have been widely used as configurationally stable chiral building blocks for the synthesis of enantiopure β-substituted α-AAs [@B57]-[@B59]. Inspired by these studies, we envisioned that the ^18^F-trifluoromethylated SAAs **2L** and **2D** could be synthesized stereoselectively from serine-derived cyclic sulfamidates *via* a nucleophilic ^18^F-trifluoromethylthiolation reaction followed by a deprotection reaction.

The initial step in our work was to synthesize the cyclic sulfamidates **3L** and **3D** *via* a four-step reaction (**Scheme [S1](#SM0){ref-type="supplementary-material"}**), according to the reported methods [@B12], [@B58], [@B60]-[@B62]. With the desired cyclic-sulfamidates in hand, we set out to optimize the reaction conditions (**Table [S1](#SM0){ref-type="supplementary-material"}**) and to explore the synthesis of **2L** and **2D**. As shown in **Scheme [1](#SC1){ref-type="fig"}**, the ^18^F-trifluoromethylthiolation of cyclic-sulfamidates **3L** and**3D** (2 mg, 6 μmol) with PDFA (1.5 mg, 6 μmol) and S~8~ (3.0 mg, 12 μmol) in the presence of heating-block-dried K~2.2.2~/K^18^F was carried out at 70 ^o^C for 5 min to give the radiolabelled intermediates **4L** and**4D** which were subsequently purified by the C18 cartridge and eluted with ethanol. Then, the solution was evaporated and hydrolyzed in 4N HCl aq. at 90 ^o^C for 10 min [@B61], [@B62]. Finally, the desired products **2L** and **2D** were neutralized (pH ≈ 6) and isolated using solid phase extraction to obtain 14% ± 3% RCY (*n* = 6) in 35 min. The radiochemical purity was higher than 98%, as determined by radio-TLC (**Figure [S2](#SM0){ref-type="supplementary-material"}-3**) [@B63]. Similar to a previous report about the synthesis of non-radiolabelled L-trifluoromethylcysteine [@B64], the harsh hydrolysis conditions failed to lead to a β-elimination side reaction, suggesting a good stability of **2L** and **2D** in acidic conditions. **2L** and **2D** had log*P* values of -2.75 and -2.22, respectively, and were \> 95% stable in PBS at 37 ^o^C for up to 2 hours (**Figure [S5](#SM0){ref-type="supplementary-material"}**). According to the chiral radio-HPLC analysis, almost no racemization was detected during the synthesis of **2L** and **2D** (optical purity: *ee* \> 99%; **Figure [2](#F2){ref-type="fig"}** and **Figure [S4](#SM0){ref-type="supplementary-material"}**), which forcefully confirmed the feasibility of this nucleophilic ^18^F-trifluoromethylthiolation protocol (**Scheme [S2](#SM0){ref-type="supplementary-material"}**) for synthesizing enantiopure ^18^F-trifluoromethylated cysteines.

*In vitro* cell research
------------------------

Encouraged by the successful synthesis of **2L** and **2D**, we conducted *in vitro* cell uptake study to explore the specificity of each enantiomer. As shown in **Figure [3](#F3){ref-type="fig"}A**, the uptake of **2L** in C6 cells increased steadily in a time-dependent manner, and the maximal value (4.33% uptake/100 μg protein) appeared at the 120 min. **2D** rapidly accumulated in the cells within a short time and reached a maximum of about 6.34% uptake/100 μg protein after incubation for 20 min, but then declined slowly afterward. One possible reason for the above situation was that **2D** was being transported into/out of the C6 cells at a higher rate compared with **2L**. Thus, the uptake of **2L** was higher than that of **2D** in C6 cells after approximately 60 min, and the uptake difference was gradually enlarged with the prolonged incubation time. *In vitro* cell uptake studies indicated that cysteines functionalized with an \[^18^F\]CF~3~ moiety could be taken up efficiently by C6 cells, but there was an obvious distinction between different chiral isomers on the cellular uptake efficiency.

Although mammalian cells generally tend to employ L-enantiomer for the biological basic needs, both the enantiomers of AAs can be transported [@B44]. In order to investigate the uptake mechanism of each enantiomer, a competitive inhibition study was performed using C6 glioma cells in the presence of AA transporter inhibitors (**Figure [3](#F3){ref-type="fig"}B-C**). After 15 min of incubation in choline chloride solution (-Na^+^), the cellular uptake of **2L** and **2D** was obviously decreased by BCH (2-amino-2-norbornanecarboxylic acid), a classical inhibitor for system L transporters. Additionally, the transportation of **2L** and **2D** in saline solution (+Na^+^) was effectively blocked by L-serine (Ser), a non-specific inhibitor for system ASC transporters [@B36], [@B65]. By contrast, MeAIB (2-aminoisobutyric acid), a system A inhibitor, exerted almost no significant effect on the transportation of **2L** and **2D** into the cells in either choline chloride or saline solution. Similar to ^11^C-methyl-cysteines **1L** and **1D** [@B35], [@B36], we found that the cellular uptake of both enantiomers of ^18^F-trifluoromethylated cysteine in C6 cells mainly relied on the systems L and ASC, however, the system A did not contribute to the radioactive accumulation. Remarkably, the cellular uptake of **2L** was significantly suppressed by L-MCYS (*S*-methyl-L-cysteine) in both choline chloride and saline solution (**Figure [3](#F3){ref-type="fig"}B**), strongly suggesting that L-MCYS and its mimic**2L** shared the same AA transport systems.

Next, we examined the extent of protein incorporation of each enantiomer in C6 tumor cells, according to the similar reported method [@B66]. After precipitation with trichloroacetic acid (TCA), the protein incorporation of **2L** in C6 cells was 0.6% and 4.5% at 30 and 120 min incubation times (**Figure [3](#F3){ref-type="fig"}D**), respectively. Thus, there was almost no incorporation of **2L** into protein. In comparison, a markedly higher percentage of **2D** incorporated into protein, with about 5% and 13% at 30 and 120 min, respectively, implying that there were some interactions between **2D** and intracellular macromolecules (perhaps enzymes). Overall, the *in vitro* cell studies fully demonstrated that cellular uptake of ^18^F-trifluoromethylated cysteines was mainly associated with their AA transport systems across the cell membrane rather than with the protein incorporation.

*In vivo* biodistribution studies
---------------------------------

To explore the *in vivo* biodistribution of each enantiomer, we subsequently performed the studies by dissection on normal Kunming mice (*n* = 4 per group). Surprisingly, a rapid and progressive accumulation of radioactivity was observed in the bone from 5 to 90 min after injection of **2L** (**Figure [4](#F4){ref-type="fig"}A**). But for **2D**, the bone uptake only slightly increased over time (**Figure [4](#F4){ref-type="fig"}B**), suggesting a slow defluorination or a bone marrow uptake. Even though both **2L** and **2D** were stable *in vitro*, there was a marked difference in stability between the two enantiomers *in vivo*. One reasonable explanation is that **2L** might serve as a preferential substrate for cysteine *S*-conjugate β-lyases and underwent an enzyme-catalyzed β-elimination reaction [@B67], [@B68]. Structurally,**2D** is also a cysteine *S*-conjugate but showed relatively good *in vivo* stability, presumably because the β-elimination reaction proceeded with high L-stereoselectivity. On the basis of these analyses, a possible mechanism was proposed to explain the surprising *in vivo* instability of **2L**. As illustrated in **Scheme [2](#SC2){ref-type="fig"}**, the deprotonated base (B^-^) abstracts a proton from **2L** and initiates transaldimination of pyridoxal 5\'-phosphate (PLP)-imine with the deprotonated α-amino group to form the **2L**-PLP Schiff base [@B69], [@B70]. The Schiff base is then α-deprotonated by the ε-amino group of the lysine residue to give a quinoid intermediate [@B71], [@B72]. Subsequent elimination of \[^18^F\]trifluoromethanethiol (\[^18^F\]CF~3~SH further decomposes to release ^18^F-fluoride; please see the green box in **Scheme [2](#SC2){ref-type="fig"}**) from the β-carbon position produces a ketimine intermediate which is finally hydrolyzed to afford PLP-imine, pyruvate and ammonium [@B69], [@B73].

In addition, biodistribution studies by dissection indicated that **2D** was primarily excreted *via* the kidneys (urinary system) and to a minor extent *via* the hepatic route. Fast washout of radioactivity from the main tissues and organs (*e.g.*, blood, heart, lung, pancreas, and stomach) was observed during the entire experimental process (**Figure [4](#F4){ref-type="fig"}B**), revealing that **2D** has advantages of rapid *in vivo* clearance. Similar to **1L** and **1D** [@B35], [@B36], [@B39], low accumulation of **2D** in the brain was found in the biodistribution data, which could be considered as an advantage or a disadvantage. It was an advantage because the tracer with low brain uptake would contribute to providing a low background activity for PET imaging of brain tumors. On the other hand, it could also be a disadvantage for the tracer, as the uptake in any cranial tumor would be low due to a low availability of the tracer after transport through the blood-brain barrier. Moreover, we also performed a comparison between \[^18^F\]FDG and **2D** in Kunming mice (*n* = 4 per group) with turpentine-induced acute inflammation. The preliminary results (data obtained by dissection) showed that **2D** had significantly lower inflammation/muscle and inflammation/blood ratios than \[^18^F\]FDG at 60 min post-injection (**Table [S2](#SM0){ref-type="supplementary-material"}**), which was similar to our previous report on **1D** [@B40].

*In vivo* PET imaging of *S*-\[^18^F\]CF~3~-D-CYS
-------------------------------------------------

The promising results from *in vitro* cell uptake studies and *in vivo* biodistribution studies, such as specific tumor-targeting properties and favourable pharmacokinetic characteristics, inspired us to further investigate the feasibility of **2D** as an amino acid tracer for glioma PET imaging. As shown in **Figure [5](#F5){ref-type="fig"}A**, the D-enantiomer selectively accumulated in C6 tumor tissues to give a good tumor-to-background contrast, which was predominantly cleared by renal excretion with moderate liver accumulation. The average uptake values of **2D** in the tumor were 3.81 ± 0.23, 3.74 ± 0.18, 3.56 ± 0.15% ID/g (*n* = 3) at 45, 60 and 75 min after injection, respectively. Compared with \[^18^F\]FDG, **2D** exhibited relative less tumor radioactivity accumulation but much lower uptake in most major organs (except of pancreas, kidney and bladder), particularly in normal brain tissue (**Figure [5](#F5){ref-type="fig"}A-B**). Hence, the tumor-to-brain uptake ratio of **2D** was substantially higher than that of \[^18^F\]FDG (**Figure [5](#F5){ref-type="fig"}C**). In addition, a slightly high **2D** uptake was observed in the muscle tissues, which might restrict the application of the D-enantiomer in regions beyond the brain.

To further determine the distribution patterns of **2D**, a 90 min dynamic micro-PET scan was performed in other C6-bearing mice (**Figure [S6](#SM0){ref-type="supplementary-material"}**). The time-activity curves were obtained from dynamic images after drawing regions of interest (**Figure [6](#F6){ref-type="fig"}A**). Relative uptake ratios of tumor-to-brain, tumor-to-muscle and tumor-to-bone at different time points were then calculated and illustrated in **Figure [6](#F6){ref-type="fig"}B**. During the first 30 min, **2D** reached its maximum uptake value and exhibited a long-term retention in the C6 tumor, then declined slowly. The highest tumor-to-brain uptake ratio of 14.70 was achieved at 15 min after injection of **2D**. It was also noteworthy that the bone uptake increased slightly as time went on, which was consistent with the results of the biodistribution studies. Even so, several competing factors should be considered synthetically in the process of defining PET images, such as tumor tissue uptake, *in vivo* defluorination or bone marrow accumulation, and pharmacokinetic characteristics [@B74]. Additional investigations are warranted in the future to ascertain *in vivo* metabolic fate of the ^18^F-trifluoromethylated cysteines as well as their stability *in vitro* in the presence of the cysteine *S*-conjugate β-lyases. Taken together, these results showed that *S*-\[^18^F\]CF~3~-D-CYS **2D**, an \[^18^F\]CF~3~-functionalized SAA tracer, might be a potential candidate for glioma imaging.

Conclusions
===========

In conclusion, we have successfully designed and synthesized a couple of ^18^F-trifluoromethylated cysteine enantiomers (**2L** and **2D**) according to a structure-based bioisosterism strategy. *In vitro* study indicated that cellular uptake of the two enantiomers was primarily associated with AA transport systems L and ASC. Notably, *in vivo* biodistribution and PET imaging studies demonstrated that **2D** was characterized with relatively good stability and high tumor-specific accumulation. Our results suggest that ^18^F-trifluoromethylated D-cysteine, a new SAA tracer, may be a potential candidate for PET imaging of glioma. To the best of our knowledge, this is the first study to synthesize enantiopure ^18^F-trifluoromethylated cysteines and to evaluate their feasibility as "structure-mimetic" AA tracers for tumor imaging. Also, a more detailed biological evaluation is underway.

Materials and Methods
=====================

Radiochemistry
--------------

^18^F-fluoride was trapped on a QMA light cartridge and subsequently eluted by a H~2~O/CH~3~CN (1:9, 1.0 mL) mixed solution of K~2~CO~3~ (3 mg) and K~2.2.2~ (13 mg) into a sealed penicillin bottle (10 mL). The K~2.2.2~/K^18^F solution was evaporated at 95 ^o^C for 10 min under a N~2~ flow and resolubilized in anhydrous CH~3~CN (1.0 mL). The resulting solution of K~2.2.2~/K^18^F in anhydrous CH~3~CN was entirely transferred into a 10 mL volumetric penicillin bottle (sealed by a rubber cap) containing the cyclic-sulfamidate precursor (**3L** or **3D**; 2 mg, 6 μmol), PDFA (1.5 mg, 6 μmol) and S~8~ (3.0 mg, 12 μmol). The nucleophilic ^18^F-trifluoromethylthiolation reaction was carried out at 70 ^o^C for 5 min without electromagnetic stirring. After the reaction completed, the reaction mixture was diluted by 5% AcOH aqueous solution (10 mL) and passed through a C18 plus short cartridge. After washed by sterilized water (10 mL), the ^18^F-labelled intermediate **4L** or **4D** was eluted from C18 cartridge by ethanol (1.5 mL) into another sealed penicillin bottle. The solvent was removed by evaporation at 85 ^o^C for 5 min under a N~2~ flow. 4 N HCl aq. (0.8 mL) was added to the residue and heated for 10 min at 90 °C. Finally, the product (**2L** or **2D**) was purified by passing serially through an AG 11 A8 ion retardation resin column, a Sep-Pak alumina N plus light cartridge, a C18 plus short cartridge, and a sterile Millipore 0.22 μm filter with 0.9% NaCl aq. solution (2 mL) into a final product vial (pH ≈ 6).

A detailed descriptions of all experimental procedures, including organic chemistry synthesis, radiochemistry synthesis, and *in vitro* and *in vivo* biological evaluation experiments, can be found in the [Supplementary Materials](#SM0){ref-type="supplementary-material"}.
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![**(A)** Chemical structures of *S*-\[^11^C\]CH~3~-L-CYS **1L** and *S*-\[^11^C\]CH~3~-D-CYS **1D** using isotopic substitution of -CH~3~ with -\[^11^C\]CH~3~ in our previous studies; **(B)** Chemical structures of *S*-\[^18^F\]CF~3~-L-CYS **2L** and *S*-\[^18^F\]CF~3~-D-CYS **2D** using bioisosteric replacement of -CH~3~ with -\[^18^F\]CF~3~ in this study; **(C)** Molecular electrostatic potential (MEP) maps of *S*-CH~3~-L-CYS, *S*-CH~3~-D-CYS and their mimics were carried out at the B3LYP/6-31G (*d, p*) level using the Gaussian^®^ 09W computational package in the water phase (the blue indicates the distribution of positive charge, and the red indicates the distribution of negative charge). As shown, *S*-CF~3~-L-CYS and *S*-CF~3~-D-CYS are nearly identical in structural arrangement and charge distribution pattern to*S*-CH~3~-L-CYS and *S*-CH~3~-D-CYS, respectively.](thnov09p1144g001){#F1}

![Synthesis of ^18^F-trifluoromethyl cysteine enantiomers **2L** and **2D** *via* nucleophilic ^18^F-trifluoromethylthiolation. Reagents and conditions: a. PDFA, S~8~, K~2.2.2~/K^18^F, CH~3~CN, 70 ^o^C, 5 min; b. 4N HCl aq., 90 ^o^C, 10 min.](thnov09p1144g002){#SC1}

![Chiral radio-HPLC analysis of **2L** and **2D** (test tube method^\#^).](thnov09p1144g003){#F2}

![**(A)** Time-dependent cell uptake assays with **2L** and **2D** in C6 cells; **(B)** Competitive inhibition of C6 cell uptake of *S*-\[**^18^**F\]CF~3~-L-CYS **2L** after co-incubation with each inhibitor or L-MCYS for 15 min; **(C)** Competitive inhibition of C6 cell uptake of *S*-\[^18^F\]CF~3~-D-CYS **2D** after co-incubation with each inhibitor for 15 min; **(D)** The comparison of protein incorporation of **2L** and **2D** in C6 tumor cell line after incubation for 30 min and 120 min.](thnov09p1144g004){#F3}

![**(A)** The biodistribution of **2L** in normal Kunming mice at 5, 30, 60 and 90 min post-injection; **(B)** The biodistribution of **2D** in normal Kunming mice at 5, 30, 60 and 90 min post-injection.](thnov09p1144g005){#F4}

![Possible mechanism of cysteine *S*-conjugate β-lyases catalyzed β-elimination of *S*-\[^18^F\]CF~3~-L-CYS **2L**. PLP, the biologically active cofactor*,* is bound to the enzyme (Enz) at the ε-amino group of the lysine residue.](thnov09p1144g006){#SC2}

![**(A)** Static micro-PET images of C6 glioma-bearing mice scanned at 45, 60 and 75 min after injection of *S*-\[^18^F\]CF~3~-D-CYS **2D** and at 60 min after injection of \[^18^F\]FDG (the white arrow indicates the tumor); **(B)** Image-derived biodistribution data of **2D** (at 45, 60 and 75 min post-injection) and \[^18^F\]FDG (at 60 min post-injection) in most major organs and tumor; **(C)** Comparison of tumor-to-brain uptake ratios between **2D** and \[^18^F\]FDG at different time points post-injection.](thnov09p1144g007){#F5}

![**(A)** Time-activity curves of brain, muscle, bone, tumor, liver, kidney and bladder uptake in BALB/c nude mice bearing C6 tumor after injection of **2D**; **(B)** Relative uptake ratios of tumor-to-brain, tumor-to-muscle and tumor-to-bone at different time points (0 to 90 min) after injection of **2D.**](thnov09p1144g008){#F6}
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